£795.00

The 2023-2028 World Outlook for Medical Foods for Inborn Errors of Metabolism

Subjects

Price data last checked 156 day(s) ago - refreshing...

View at Amazon

We'll watch every seller, every day. One email when your price arrives.

It has never been this cheap. We have no record of a lower price.

£795 today · cheaper than every other day in the last 24 months

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↓ Price chart
when this has been cheap or pricey

↓ Forecast
where the price is heading next

↓ Statistics
all-time high & low, recent range

↑ Price alert
name your number, we'll email you

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 575 days • 575 data points (No recent data available)

Historical

Generating forecast...

Price Distribution

Price distribution over 575 days • 1 price levels

Days at Price

Price Analysis

Most common price: £795 (575 days, 100.0%)

Price range: £795 - £795

Price levels: 1 different prices over 575 days

Description

This study covers the world outlook for medical foods for inborn errors of metabolism across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved. In this report we define the sales of medical foods for inborn errors of metabolism as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Abbott, Ajinomoto Cambrooke, Inc. (A subsidiary of Ajinomoto), APR, BioMarin Pharmaceutical, Dr.Schar AG/SPA Primus Pharmaceuticals, Inc., Ener-G Foods, Nestlé Health Science, Nutricia (A subsidiary of Danone), PKU-MDmil, Poa Pharma, Pristine Organics Pvt, Promin Metabolics, Reckitt Benckiser Group, and Solace Nutrition. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).

Product Specifications

Format: paperback
ASIN: B09YHQRC4Q
Category: Books > Subjects
Domain: Amazon UK
Release Date: 10 May 2022
Listed Since: 06 May 2022

The 2023-2028 World Outlook for Medical Foods for Inborn Errors of Metabolism

It has never been this cheap. We have no record of a lower price.

Price History & Forecast

Price Distribution

Price Analysis

Description

Product Specifications

Similar Products You Might Like

The 2023-2028 Outlook for Protein Ingredients for US Zip Codes

The 2023-2028 Outlook for Functional Polyphenol Beverages in the United States

The 2023-2028 Outlook for Liquid Milk Replacers in Japan

The 2025-2030 World Outlook for Sodium Butyrate

The 2023-2028 Outlook for Probiotic Dietary Supplements for US Zip Codes

The 2023-2028 Outlook for Probiotic Dietary Supplements in the United States

The 2023-2028 Outlook for Digestive Health Products in China

The 2023-2028 Outlook for Probiotic Dietary Supplements in Japan

The 2023-2028 Outlook for Sports Nutrition Products in India

The 2023-2028 Outlook for Sports Nutrition Products for US Zip Codes

The 2023-2028 Outlook for Sports Nutrition Products in Japan

The 2026-2031 World Outlook for Flavored Yogurts

The 2023-2028 World Outlook for Sports Nutrition Products

The 2023-2028 Outlook for Sports Nutrition Products in the United States

The 2023-2028 World Outlook for Functional Non-Meat Ingredients

The 2025-2030 World Outlook for Sports Nutrition Products

The 2026-2031 World Outlook for Flavored Syrups

A.S.P.E.N. Adult Nutrition Support Core Curriculum

The 2023-2028 Outlook for Fine Mist Sprayers in Japan

Advanced Nutrition and Regulation of Metabolism

Nutrition in Infancy: Volume 2 (Nutrition and Health)

Nestlé - Eine Analyse der Wettbewerbsvorteile im Vergleich zu Danone und Unilever

Reformulation as a Strategy for Developing Healthier Food Products: Challenges, Recent Developments and Future Prospects

The 2023-2028 Outlook for Non-Alcoholic Concentrated Syrups in Japan